This study involves the administration of a monoclonal antibody called OpSCF subcutaneously (given as an injection under the skin like a flu shot) every 2 weeks. Participants who are determined to meet the requirements to take part in the study will have a 50% chance (like flipping a coin) of receiving the active study drug or placebo (does not have active study drug in it) for the first part of the study (for about 16 weeks).
Compensation may be provided for time and travel. Participation will come at no cost to you.
Visits
Drug administered on which days
Total
Length
Procedures
Study Length
Days
Number of times study drug will be given: 17
Total
22 visits + 2 follow-ups (1 in-person visit and 1 follow-up phone call)
Length
On average 2-2.5h, with 4-5 hours for the longest on the first day that you are given your first dose of study drug
Procedures
Blood will be taken from you and at certain visits, and if you agree, skin samples and photographs may also be taken.
Study Length
approx. ~71 weeks (about 16 ½ months)
Summary
We are currently recruiting subjects aged 18 to 75 years with moderate to severe Atopic Dermatitis (Eczema) to take part in a research study. The primary objective of the study is to assess the efficacy (how well the study drug works) and safety of an investigational monoclonal antibody called OpSCF.
Condition
Atopic Dermatitis (Eczema)
Treatment
OpSCF201
